Let’s just say what we’re all thinking: 2020 was rough. It threw pretty much every element of our lives into disarray, and we suddenly had to become experts at navigating a new way of working, schooling and socialising. It was disruptive, and it was challenging, but it was also transformative. While the past 12 months might have felt like 12 years, it’s time to look forward to what the future holds. If 2020 was the year of disruption, 2021 will be the year of mastering change.
Precision medicine, or personalised medicine, offers unprecedented opportunities for life sciences companies and patients alike. In addition to establishing a new paradigm of care, personalised medicine also introduces dramatic change and a set of evolving rules. By embracing digital technologies, data management and supply chain tools, and approaching regulatory change as a strategic differentiator, companies can adapt their businesses to the new rules of personalised medicine and reap the benefits.
In the full article linked below, SeerPharma's business partner MasterControl explores the following key topics:
Harnessing Digital Transformation to Drive Medical Innovation
Digital transformation was already underway in precision medicine before 2020, as the technologies that underpin health care have been evolving rapidly. However, the year’s events have pushed even the slow adopters to embrace digitisation, including telemedicine/telehealth applications and mobile medical apps, or the integration of smartphones and tablets into health care. The COVID-19 pandemic has brought to light the importance of digitisation and flexibility, particularly in environments where harnessing new technologies can help life sciences companies quickly and affordably create complex, patient-specific devices and accelerate time to market.
Unifying Data Sources and Insights Creates a Closed-Loop Ecosystem
As new technologies make advances in precision medicine possible, they are also generating vast amounts of data that can include clinical studies, laboratory data, patient information, product data and much more. As technologies create and provide enormous, disparate data sets, organisations must be able to track, store and analyse them quickly and accurately. To achieve the benefits of digital transformation – namely greater connectivity and interoperability, increased visibility and more data-driven insights – organisations must harness all that data through integration and analysis across multiple data sets.
Supply Chain Agility Demands a Modern Approach to Technology
With personalised medicine, which requires live cells and where the production cycle begins and ends with the patient, the supply chain stakes are high. The large-scale supply chain disruption caused by the COVID-19 pandemic has highlighted how a bottleneck or slowdown at even one point in the supply chain can significantly disrupt the manufacture of these products.
Embracing Regulatory Change as a Point of Strategic Differentiation
The advancement of personalised medicine has raised new challenges related to regulatory oversight, as the landscape for the regulation of personalised medicine is still evolving.
Submit the form below to access the full MasterControl article Monitoring the Pulse of Precision Medicine: 2021 Trends in Personalised Medicine.
